The role of serological testing in the SARS-CoV-2 outbreak by Mayne, E S et al.
1       Published online ahead of print
IN PRACTICE
SARS-CoV-2 is a novel coronavirus that originated in Wuhan 
Province, China, in late 2019. Phylogenetic analysis suggests that 
this virus shows homology with other Betacoronaviridae, including 
the viruses responsible for the severe acute respiratory syndrome 
(SARS) outbreak in South-East Asia and the Middle East respiratory 
syndrome (MERS) outbreak in the Middle East.[1] A zoonotic reservoir 
was identified in both these cases, and it is thought that SARS-CoV-2 
is also zoonotic, with possible intermediate hosts including bats and 
pangolins (although these have not been conclusively identified).[1]
South Africa (SA) has the highest number of infections with 
SARS-CoV-2 in Africa, with >100 000 cases and >2 000 deaths 
reported as of the middle of June 2020. In March, a National State of 
Disaster was declared, followed shortly afterwards by declaration of a 
national lockdown that was one of the most stringent in the world. [2] 
The lockdown was a mitigation strategy to build diagnostic and 
health capacity and infrastructure and to protect at-risk populations 
(including the immunocompromised, the elderly, and patients with 
underlying chronic conditions).[3-5] A critical component in this strategy 
is the rapid identification and isolation of individuals who are infected 
and can transmit infection and the quarantine of their contacts, even if 
they are asymptomatic or presymptomatic.[6-12] Challenges have arisen 
with the molecular reverse transcription polymerase chain reaction 
(RT-PCR) testing, which have resulted in backlogs and prolonged 
turnaround times in both high- and low- to middle-income countries 
around the world. There is, therefore, an increasing global demand 
for additional testing kits and to determine strategies and the role of 
serological assays.[13-15] Difficulty with development of these strategies 
is compounded by the high numbers of testing platforms and assays 
that are entering the market and require oversight and validation in the 
context of COVID-19 disease control.
Diagnostic and screening modalities for SARS-CoV-2 include:
Molecular testing (RT-PCR, reverse transcription loop-mediated 
isothermal amplification (PT-LAMP), and clustered regularly 
interspaced short palindromic repeats (CRISPR)-based diagnostics), 
recommended for diagnosis of cases in the acute stage of infection. 
Antigen tests are in development and serve the same purpose as PCR; 
they are likely to have lower sensitivity but greater ease of use and 
access at point of care.
Serological testing, including lateral-flow antibody assays, bead-
based assays (Luminex technology), enzyme-linked immunosorbent 
assays (ELISAs) and automated serology platforms.
Clinical stratification based on symptoms and signs including 
pyrexia, upper respiratory tract symptoms including odynophagia 
and cough, nonspecific gastrointestinal symptoms including nausea 
and diarrhoea, and atypical symptoms such as anosmia, with clinical 
investigations including chest radiographs.[16-18]
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Antibody tests for the novel coronavirus, SARS-CoV2, have been developed both as rapid diagnostic assays and for high-throughput formal 
serology platforms. Although these tests may be a useful adjunct to a diagnostic strategy, they have a number of limitations. Because of the 
antibody and viral dynamics of the coronavirus, their sensitivity can be variable, especially at early time points after symptom onset. Additional 
data are required on the performance of the tests in the South African population, especially with regard to development and persistence of 
antibody responses and whether antibodies are protective against reinfection. These tests may, however, be useful in guiding the public health 
response, providing data for research (including seroprevalence surveys and vaccine initiatives) and development of therapeutic strategies.
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Serological testing
Serological testing is commonly utilised for infectious disease 
diagnosis for both viruses and bacteria. Serological testing detects 
antibodies in blood that tend to be specific to the infection and can 
be used to assess both acute infection (typically immunoglobulin M 
(IgM)), ongoing infection (typically immunoglobulin G (IgG) and 
IgM with some agents) and previous exposure (typically IgG). The 
presence of these antibodies can also be used to assess immunity to 
pathogens and to evaluate the immunogenicity of, and response to, 
some vaccines. An important factor in developing serological tests 
is determining the correct antigen or antigens to include in the test. 
Antigens are components of the pathogen against which antibodies 
are formed. The antigenic structure of some organisms is highly 
variable, which can complicate the development of sensitive and 
specific assays. Both point-of-care and laboratory-based serological 
assays for automated and manual platforms are currently available 
on the market. The South African Health Products Regulatory 
Authority (SAHPRA) is currently evaluating several commercial 
antibody assays.
The antibody response to COVID-19
The antibody response to COVID-19 develops after a period of 
weeks after symptom onset. Samples taken prior to 5 - 7 days after 
symptom onset are often antibody-negative. From extensive studies, 
it appears that the antibody response begins to form around day 5 
after symptom onset for IgM and around days 10 - 14 for IgG,[19] 
although the maximal detectable response may be even later. In 
~20% of infected individuals (with localised disease), IgG may not 
be detected at all. Immunoglobulin A (IgA), an antibody subclass 
associated with mucosal immunity, may be produced earlier and by 
more individuals than IgM or IgG. Detectable antibodies (IgM, IgG 
or IgA) appear to be more commonly produced in individuals with 
severe disease (defined as disease requiring intensive care admission 
or mechanical ventilation).[20-24]
The novel coronavirus has four major protein components against 
which antibodies are formed following infection. These are the outer 
nucleocapsid (NC), the spike (S), which includes the S1 and S2 
subunits and the receptor binding domain (RBD), the membrane (M) 
and the envelope (E).[25] The majority of current serological assays 
are designed to detect antibodies against the NC or S proteins (which 
are the most immunogenic).[25] Not all patients, however, produce 
antibodies against all of these proteins.[26]
The protective value of antibodies is not clearly understood in 
COVID-19. Antibodies directed against certain antigens (specifically 
S or RBD) are more consistently produced and may provide protection 
from reinfection.[27-30] However, seroconversion does not always 
correspond to a reduced viral load;[28] indeed, antibody levels are 
frequently higher in patients with severe disease. In some patients, 
continuous viral shedding with detectable RNA for up to 50 days 
has been reported, despite a robust IgG antibody response. [31-35] 
Prolonged viral shedding has been associated with more severe 
disease and requirements for ventilation.[32] Early data from some 
studies, including immunisation in a non-human primate model, 
suggest that antibodies may protect against reinfection, but this is not 
yet conclusive.[36]
Types of serological tests for COVID-19
The two basic categories of serological tests currently available for 
COVID-19 are rapid diagnostic tests (also known as point-of-care, 
bedside or near-patient tests) and formal laboratory serological 
tests.
Rapid diagnostic tests often use the lateral flow design, which 
produces a colour change on a test strip. Over 250 of these rapid 
kits have been produced (https://www.finddx.org/covid-19/sarscov2-
eval-immuno). Many but not all of these tests include both IgM and 
IgG detection. Some of these tests have been evaluated in settings 
across the world, but a number of studies have been on smaller 
sample sizes (ranging from 5 to 25 infected individuals), and the 
sensitivity and specificity have been extremely variable, especially at 
earlier time points in the course of COVID-19.
The formal assays are either based on the ELISA or the 
chemiluminescent detection principle. At least three of these 
assays, which have become available in SA for validation, produced 
by Euroimmun, Roche Diagnostics and Abbott Diagnostics, have 
been evaluated in a number of studies and have been authorised 
for emergency use by the US Food and Drug Administration. 
The sensitivity of these assays in large validation studies has been 
variable, especially if time points prior to 14 - 21 days are considered 
or if sampled populations include asymptomatic patients.[37] Package 
inserts from the formal testing quote sensitivities ranging from 
33.3% (Euroimmun IgG) prior to 10 days after symptom onset, 
to 50% prior to day 7 (Abbott IgG assay) to 65.5% (Roche assay) 
(Table 1).
Limitations of serological testing and 
possible use cases
There is a growing call for antibody testing to be available for various 
purposes, including diagnosis. It is important, however, for clinicians 
to be aware that interpretation of results is not straightforward. 
The use of serology for diagnosis is limited by the relatively late 
onset of an IgG response and the fact that some individuals may 
not produce antibodies in the blood at all. For selective screening, 
it may be necessary to use a combination of testing strategies which 
may incorporate antibody testing, especially in individuals at later 
time points in infection. Some countries are pondering the idea of 
‘immunity passports’, but this approach is limited by our lack of 
understanding related to the protective role of antibodies and the 
possibility of false-positive or false-negative tests that are associated 
with different tests.
Specific challenges are: 
• Sensitivity. This is determined by the antigen selected for the test, 
the antibody class measured, and the time point during the disease 
course at which the test is conducted. Asymptomatic individuals 
may produce only localised antibody responses, or not have 
detectable antibody responses at all.[28]
• Specificity. This is a concern because most individuals have 
undergone previous infection with other human coronaviruses. 
Antibodies to these viruses may cross-react with SARS-CoV-2 
antigens, causing false-positive results. In addition, exposure to 
common human coronaviruses is likely to increase during the 
winter season.
• Uncertainty regarding the protection provided by antibodies. 
This limits the utility of serology to determine any conferred 
immunity to the infection. The role of antibodies may become 
clearer with additional studies, particularly in the SA population.
• Durability of the antibody response. Recent literature suggests 
that antibody responses wane rapidly after SARS-CoV-2 infec-
tion.[26]
There are, however, some specific roles that antibody tests could play. 
Unlike PCR testing, serological testing is able to detect past infection, 
increasing its scope to include outbreak surveillance where individuals 
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have been exposed, but have remained asymptomatic. Serological data 
can potentially provide information on true numbers of infections and 
enable more accurate determination of case fatality or case infection 
rates. Serological data can also be used for seroprevalence surveys, 
which will help to determine how many people in SA were previously 
infected; however, it should be noted, as per the Africa Centres for 
Disease Control and Prevention, that a negative antibody test does 
not exclude past or current infection with SARS-CoV-2 (africacdc.
org/download/interim-guidance-on-the-use-of-rapid-antibody-tests-
for-covid-19-response/), as antibody responses may wane, leading 
to false-negative results in people who have had previous infection. 
However, antibody assays may also be able to assess immune responses 
to potential vaccines. Molecular testing is still recommended for 
diagnosis during acute infection, especially in the first 7 days after 
symptom onset. Because of specificity issues, it is possible that a two-
test serological strategy may have some clinical utility (www.who.int/
publications-detail/laboratory-testing-strategy-recommendations-
for-covid-19-interim-guidance).
A list of potential applications for serological assays, including 
laboratory-based and rapid tests, could include (Fig. 1):[43-46] 
• To identify the presence of antibodies directed against COVID-
19 in the following cases (as an ancillary diagnostic test):
• To identify past exposure to SARS-CoV-2 in individuals at 
21 days post infection
• To identify antibodies in children with COVID-19-associated 
inflammatory syndrome in children.
• To investigate outbreaks in ‘hotspots’ to identify evidence of 
subclinical infections.
• Targeted cohort surveillance, e.g. for staff, patients, visitors and 
residents of facilities such as healthcare institutions, prisons and 
workplaces. Repeat antibody testing over time can allow more 
comprehensive epidemiological assessments.
• Population-level epidemiological studies and community 
surveillance programmes.
• Identification of convalescent plasma donors. For this indication, 
tests that quantify neutralising antibodies or that correlate with 
neutralising antibody titres will be required.
• As part of scientific research studies, e.g. antibody reactivity as 
a prognostic marker, for SARS-CoV-2 vaccine trials, additional 
validation, etc.
Conclusions
It is clear that serological testing, both at point of care and formal, 
can have high utility. This is especially true in research settings. 
Interpretation of a negative assay should be performed with caution, 
especially in asymptomatic individuals or individuals with recent 
onset of symptoms. Despite potential concerns regarding cross-
reactivity with other viruses, the high specificity of these assays 
can provide reassurance that individuals who test positive have 
probably been exposed to the infection. It must be noted, however, 
that this does not necessarily indicate that the patients are no longer 
infectious.
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